SINGULAR GENOMICS SYSTEMS IN (OMIC)
US82933R1005 - Common Stock
Overall OMIC gets a fundamental rating of 2 out of 10. We evaluated OMIC against 58 industry peers in the Life Sciences Tools & Services industry. The financial health of OMIC is average, but there are quite some concerns on its profitability. OMIC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year OMIC has reported negative net income.
OMIC had a negative operating cash flow in the past year.
In the past 5 years OMIC always reported negative net income.
OMIC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -35.72%, OMIC is not doing good in the industry: 82.76% of the companies in the same industry are doing better.
With a Return On Equity value of -52.97%, OMIC is not doing good in the industry: 77.59% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.72% | ||
| ROE | -52.97% | ||
| ROIC | N/A |
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OMIC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OMIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OMIC has more shares outstanding
The debt/assets ratio for OMIC is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -2.03, we must say that OMIC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.03, OMIC is not doing good in the industry: 82.76% of the companies in the same industry are doing better.
OMIC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.05, OMIC is doing good in the industry, outperforming 60.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.03 |
ROIC/WACCN/A
WACC12.63%
2.3 Liquidity
OMIC has a Current Ratio of 10.51. This indicates that OMIC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.51, OMIC belongs to the top of the industry, outperforming 91.38% of the companies in the same industry.
OMIC has a Quick Ratio of 9.77. This indicates that OMIC is financially healthy and has no problem in meeting its short term obligations.
OMIC's Quick ratio of 9.77 is amongst the best of the industry. OMIC outperforms 91.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.51 | ||
| Quick Ratio | 9.77 |
3. Growth
3.1 Past
OMIC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.15%.
OMIC shows a strong growth in Revenue. In the last year, the Revenue has grown by 278.05%.
EPS 1Y (TTM)-3.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-10.34%
Revenue 1Y (TTM)278.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q40.39%
3.2 Future
The Earnings Per Share is expected to grow by 12.40% on average over the next years. This is quite good.
OMIC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 138.83% yearly.
EPS Next Y9.29%
EPS Next 2Y8.2%
EPS Next 3Y12.4%
EPS Next 5YN/A
Revenue Next Year-7.6%
Revenue Next 2Y185.02%
Revenue Next 3Y138.83%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OMIC. In the last year negative earnings were reported.
Also next year OMIC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as OMIC's earnings are expected to grow with 12.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.2%
EPS Next 3Y12.4%
5. Dividend
5.1 Amount
No dividends for OMIC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SINGULAR GENOMICS SYSTEMS IN
NASDAQ:OMIC (4/29/2024, 3:30:02 PM)
0.3975
-0.01 (-1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap29.39M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.72% | ||
| ROE | -52.97% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.51 | ||
| Quick Ratio | 9.77 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-3.15%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)278.05%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y